Paolo Tarantino: Recommended read on adjuvant ribociclib in preparation for the ESMO24

Oncology Brothers shared a post by Paolo Tarantino on X, adding:

“Adjuvant abemaciclib preferred for high-risk HR+ EBC due to longer follow-up, deeper benefits, and shorter time of treatment. For patients intolerant to abema, ribociclib could be an option, especially for those outside monarchE with high-risk features.”

Quoting Paolo Tarantino’s post:

“Hot off the press in Annals Oncology: Is adjuvant ribociclib ready for prime time?

Recommended read in preparation for the NATALEE 4y update at ESMO24.”

Is adjuvant ribociclib ready for prime time? | ESMO Annals of Oncology

Source: Oncology Brothers/X and Paolo Tarantino/X

Drs. Rohit Gosain and Rahul Gosain (aka Oncology Brothers), are medical oncologists/hematologists. Through their social media platforms like X/Twitter, they actively engage with their audience. With their own YouTube channel and podcast, they provide accessible resources for cancer patients and their families.

Additionally, their participation in live conferences ensures that cancer patients receive the best care closer to home, reflecting their commitment to advancing oncology and improving patient outcomes through education and outreach.

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a  publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.